Cyril Amarchand Mangaldas advised The Chemours Company FC, LLC (“Chemours”)(NYSE:CC), a global chemistry company with leading market positions in Thermal & Specialized Solutions (TSS), Titanium Technologies (TT), and Advanced Performance Materials (APM) , in structuring and executing a complex cross-border arrangement with SRF Limited (“SRF”), one of India’s diversified, chemical-based multi-business conglomerates. Under this arrangement, Chemours has entered into strategic agreements with SRF for the production of certain fluoropolymers and fluoroelastomers, which Chemours will use to strengthen its global supply chain footprint, bolster operational flexibility, and provide access to capacity for these essential materials.
By leveraging SRF’s established manufacturing excellence alongside Chemours’ advanced product technology and rigorous quality standards, the collaboration will deliver a reliable supply of high-quality products. The agreements will supplement Chemours’ existing global operations, allowing Chemours to efficiently bring supply flexibility while requiring no upfront capital investment.
“This arrangement with SRF exemplifies our Pathway to Thrive strategy as we continue to shift our product mix to higher value applications, enhancing our position as a trusted supplier paired with our commitment to responsible manufacturing practices,” said Denise Dignam, Chemours President and CEO.
The CAM team assisted on end-to-end structuring of the transaction and finalisation of the transaction documents. The transaction was led by Soumya Srivastava, Partner; with support from Samaksh Khanna, Associate. Kaustav Kundu, Partner; assisted in competition aspects of the transaction.